Evidence map›Paper›PMID 32511951›Full record

ReviewThe lancet. Gastroenterology & hepatology2020

Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective.

Aisling Barry, Smith Apisarnthanarax, Grainne M O'Kane, Gonzalo Sapisochin, Robert Beecroft, Riad Salem, Sang Min Yoon, Young-Suk Lim, John Bridgewater, Brian Davidson and 9 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The lancet. Gastroenterology & hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Is cancer a prognostic factor for severe COVID-19, especially for breast cancer patients?Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2022
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review of the risk factors for SARS-CoV-2 transmission.World journal of clinical cases · 2021
    Review
  17. Review
  18. Article
  19. Cancer treatment in the coronavirus disease pandemic.Lung cancer (Amsterdam, Netherlands) · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 7 countries.

Aisling BarryDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada; Radiation Medicine Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada. Electronic address: aisling.barry@rmp.uhn.ca.
Smith ApisarnthanaraxSeattle Cancer Care Alliance, and Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
Grainne M O'KaneDepartment of Medical Oncology and Haematology, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Gonzalo SapisochinPrincess Margaret Cancer Centre, and Department of Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Robert BeecroftDepartment of Medical Imaging, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Riad SalemDepartment of Interventional Radiology, Northwestern University, Chicago, IL, USA.
Sang Min YoonDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Young-Suk LimDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
John BridgewaterUCL Cancer Institute, University College London, London, UK.
Brian DavidsonDepartment of Surgical Biotechnology, UCL Division of Surgery and Interventional Science, University College London, London, UK.
Marta ScorsettiRadiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Luigi SolbiatiRadiology Department, Humanitas Clinical and Research Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Adam DiehlDepartment of Medical Oncology, University of Washington, Seattle, WA, USA.
Pablo Munoz SchuffeneggerRadiation Oncology Unit, Department of Hematology Oncology, Pontifical Catholic University of Chile, Santiago, Chile.
Jonathan G ShamDepartment of Surgery, University of Washington, Seattle, WA, USA.
David CavallucciDepartment of Surgery, Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, QLD, Australia.
Zita GalvinMulti-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Laura A DawsonDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada; Radiation Medicine Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Maria A HawkinsUCL Cancer Institute, University College London, London, UK; Department of Medical Physics and Biomedical Engineering, University College London, London, UK.
Toronto General Hospital · CAUniversity College London · GBAsan Medical Center · KRUniversity Health Network · CAUniversity of Washington · USHumanitas University · ITIRCCS Humanitas Research Hospital · ITNorthwestern University · USPontificia Universidad Católica de Chile · CLUniversity of Queensland · AUUniversity of Toronto · CAUniversity of Washington Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.

Indexed as

PandemicsBetacoronavirusBile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaClinical Decision-MakingCoronavirus InfectionsCOVID-19HumansLiver NeoplasmsNeoplasm StagingPatient Care TeamPneumonia, ViralRisk FactorsSARS-CoV-2

Identifiers

PMID32511951
PMCPMC7274990
OpenAlexW3033337702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.